Lakefront Biotherapeutics (LKFT) Net Margin (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Net Margin for 13 consecutive years, with 223.61% the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Margin rose 42821.0% year-over-year to 223.61%; the TTM figure through Mar 2026 stood at 47.1% (up 12103.0% YoY), while the FY2025 annual figure was 28.85%, up 197.0% from the prior year.
• Net Margin grew to 223.61% in Q1 2026 per LKFT's latest filing, from 86.83% in the prior quarter.
• Across five years, Net Margin topped out at 223.61% in Q1 2026 and bottomed at 284.23% in Q3 2025.
• Historically, Net Margin has averaged 0.07% across 5 years, with a median of 8.48% in 2023.
• Annual changes were most pronounced in 2022 — Net Margin surged 260706 bps — and 2025, when it slumped 34911 bps.
• Lakefront Biotherapeutics' Net Margin stood at 114.63% in 2022, then soared by 222 bps to 140.3% in 2023, then soared by 57 bps to 220.06% in 2024, then tumbled by 61 bps to 86.83% in 2025, then jumped by 158 bps to 223.61% in 2026.
• Business Quant data shows LKFT's Net Margin at 223.61% in Q1 2026, 86.83% in Q4 2025, and 284.23% in Q3 2025.